<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03366883</url>
  </required_header>
  <id_info>
    <org_study_id>TianjinCIH20171114</org_study_id>
    <nct_id>NCT03366883</nct_id>
  </id_info>
  <brief_title>Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC</brief_title>
  <official_title>A Phase III Trial Comparing Paclitaxel, Cisplatin Plus 5-FU (TCF) Versus Radiotherapy With Paclitaxel Plus Cisplatin (TC-RT) as Preoperative Therapy for Locally Advanced Esophageal Squamous Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III clinical trail which Comparing Paclitaxel, Cisplatin Plus 5-FU (TCF)
      Versus Radiotherapy with Paclitaxel Plus Cisplatin (TC-RT) as Preoperative Therapy for
      Locally Advanced Esophageal Squamous Cancer. The Preoperative chemoradiotherapy with radical
      surgery is the standard treatment in China. But, many patients do not receive this treatment
      for many other reasons. Most of them refused or abandon radiotherapy because of the
      Intolerable adverse effects of radiotherapy, so we have launched a randomized controlled
      trial to confirm the non-inferiority of TCF over chemoradiotherapy with TC (TC-RT) as
      preoperative therapy for locally advanced esophageal squamous cancer in overall survival.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 4, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>3years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>All participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of R0 resection</measure>
    <time_frame>up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Esophageal Cancer Stage IIB</condition>
  <condition>Esophageal Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>&quot;Paclitaxel, Cisplatin Plus 5-FU (TCF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preoperative radiochemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Paclitaxel, Cisplatin Plus 5-FU (TCF)</intervention_name>
    <description>preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks)</description>
    <arm_group_label>&quot;Paclitaxel, Cisplatin Plus 5-FU (TCF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy</intervention_name>
    <description>preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week)</description>
    <arm_group_label>Preoperative radiochemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven squamous cell carcinoma.

          -  All lesions are located in the thoracic esophagus.

          -  Clinical stages IIB and III (excluding T4) based on the 7th UICC-TNM classification.

          -  20-75 years old.

          -  ECOG performance status of 0 or 1.

          -  Measurable lesions not required.

          -  No prior therapy against esophageal cancer except for complete resection by endoscopic
             mucosal resection/endoscopic submucosal dissection with either pM1/M2 disease or pM3
             disease without vascular infiltration.

          -  No prior chemotherapy, radiotherapy or hormonal therapy against any cancers

          -  Adequate organ function.

          -  Written informed consent.

        Exclusion Criteria:

          -  Synchronous or metachronous double cancers, except for intramucosal tumor curatively
             resected by local therapy.

          -  Active infection requiring systemic therapy

          -  Positive hepatitis B surface antigen and hepatitis B core antigen or human
             immunodeficiency virus antibody.(only positive hepatitis B surface antigen should
             receive anti-virus treatment during study)

          -  Pregnant or lactating women or women of childbearing potential.

          -  Patients requiring systemic steroid medication.

          -  Iodine hypersensitivity.

          -  Psychiatric disease.

          -  Hypersensitivity for CremophorEL.

          -  Poorly controlled diabetes.

          -  Severe emphysema or pulmonary fibrosis.

          -  Poorly controlled hypertension.

          -  Unstable angina within 3 weeks or with a history of myocardial infarction within 6
             months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yi Ba, MD,PHD</last_name>
    <phone>+8618622221230</phone>
    <email>bayi@tjmuch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TianjinCIH</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Ba, MD.PHD</last_name>
      <phone>+8613820741351</phone>
      <email>Bayi@tjmuch.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Ba, MD.PHD</last_name>
      <phone>+8613820741351</phone>
      <email>bmmhead1982@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>likun Zhou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongli Li, MD.PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting Deng, MD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xia Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming Bai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rui Liu, MD.PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shaohua Ge, MD.PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Le Zhang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tao Ning, MD.PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhentao Yu, MD.PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2017</study_first_posted>
  <last_update_submitted>January 7, 2018</last_update_submitted>
  <last_update_submitted_qc>January 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>preoperative chemotherapy</keyword>
  <keyword>preoperative chemoradiotherapy</keyword>
  <keyword>clinical trial</keyword>
  <keyword>phase III</keyword>
  <keyword>Esophageal squamous cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

